UOC
KROS icon

UBS O'Connor’s Keros Therapeutics KROS Stock Holding History

UBS O'Connor’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-37,891
Closed -$506K – 382
2025
Q2 		$506K Sell
37,891
-77,627
-67% -$1.05M 0.01% 272
2025
Q1 		$1.18M Buy
115,518
+64,621
+127% +$750K 0.03% 171
2024
Q4 		$806K Buy
50,897
+26,145
+106% +$1.36M 0.02% 249
2024
Q3 		$1.44M Buy
24,752
+2,299
+10% +$114K 0.04% 230
2024
Q2 		$1.03M Buy
22,453
+5,400
+32% +$290K 0.03% 291
2024
Q1 		$1.13M Buy
17,053
+2,941
+21% +$174K 0.03% 262
2023
Q4 		$561K Sell
14,112
-46,229
-77% -$1.45M 0.02% 338
2023
Q3 		$1.92M Buy
60,341
+5,000
+9% +$187K 0.03% 250
2023
Q2 		$2.22M Buy
55,341
+9,857
+22% +$432K 0.05% 275
2023
Q1 		$1.94M Buy
45,484
+166
+0.4% +$8.38K 0.05% 320
2022
Q4 		$2.18M Buy
45,318
+11,997
+36% +$560K 0.04% 447
2022
Q3 		$1.25M Sell
33,321
-24,000
-42% -$832K 0.01% 719
2022
Q2 		$1.58M Buy
57,321
+32,321
+129% +$1.42M 0.02% 699
2022
Q1 		$1.36M Buy
+25,000
New +$1.28M 0.01% 649

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

UBS O'Connor's KROS Position: Q3 2025 in Review

UBS O'Connor sold out of Keros Therapeutics (KROS) in Q3 2025, closing a stake of 37,891 shares — an estimated $506K sold.

UBS O'Connor first reported a position in KROS in Q1 2022 and held it in 14 quarters. The position peaked at $2.22M in Q2 2023. 155 funds tracked by Wall St. Rank hold KROS as of Q3 2025.

  • UBS O'Connor reported no remaining Keros Therapeutics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 37,891 Keros Therapeutics shares in Q3 2025, an estimated $506K.
  • UBS O'Connor first reported a position in Keros Therapeutics in Q1 2022 and held it in 14 quarters.
  • UBS O'Connor's Keros Therapeutics position peaked at $2.22M in Q2 2023.
  • 155 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.